Deviatoric stress-strain curves of numerical samples composed of elongated ellipsoids with different particle morphologies and particle sizes. by Yongfeng Zhu (7361045)

Subjects:

Numerical samples composed of elongated ellipsoids before and after triaxial compression. by Yongfeng Zhu (7361045)

Subjects:

Different contact patterns for two ellipsoids. by Yongfeng Zhu (7361045)

Subjects:

The normal force between two particles with De = 6.30 mm for different aspect ratios and sphericities: (a) hertz normal contact force; (b) normal viscous contact force. by Yongfeng Zhu (7361045)

Subjects:

The force chain distributions of different numerical samples composed of elongated ellipsoids with different particle morphologies and particle sizes before shearing and after load... by Yongfeng Zhu (7361045)

Subjects:

The tangential force between two particles with different aspect ratios and sphericities for De = 6.30 mm: (a) elastic tangential contact force; (b) viscous tangential contact forc... by Yongfeng Zhu (7361045)

Subjects:

Critical state parameters obtained from DEM simulations. by Yongfeng Zhu (7361045)

Subjects:

The tangential force between two particles with different equivalent diameters for P3: (a) elastic tangential contact force; (b) viscous tangential contact force. by Yongfeng Zhu (7361045)

Subjects:

Mean readiness score of modern family planning service by facility type in 2014 and 2017. by Rajon Banik (12066099)

HSP90 inhibition by RGRN-305 decreased the gene expression of proinflammatory cytokines induced by SARS-CoV-2 S protein. by Hakim Ben Abdallah (14578241)

Mean AIV-H9N2 shedding titer (Log₁₀) in oropharyngeal swabs. by Oumayma Arbani (21001472)

ECoG timescales decrease during spatial attention. by Isabel Raposo (21615517)

“…Bottom: timescales significantly decrease during covert attention relative to the attend-out condition (two locations: <i>p</i> = 0.0244; four locations: <i>p</i> < 0.0001; mean ± SEM; whiskers indicate maximum and minimum; dots correspond to individual electrodes). …”

Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects:

Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects: